拉氧头孢治疗腹腔感染的医疗资源使用分析  

An analysis of medical resource utilization in intra-abdominal infectious patients treated with latamoxef

作　　者：佟训靓[1] 肖若薇 李薇 曾春颖[3] 吴健梅 韩晟[2] TONG Xun-liang;XIAO Ruo-wei;LI Wei;ZENG Chun-ying;WU Jian-mei;HAN Sheng(Department of Pulmonary and Critical Care Medicine,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;International Research Center for Medicinal Administration,Peking University,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Fu Xing Hospital,Capital Medical University,Beijing 100038,China;Sanming First Hospital,Fujian Medical University,Sanming 365000,China)

机构地区：[1]北京医院呼吸与危重症医学科,国家老年医学中心,中国医学科学院老年医院研究院,北京100730 [2]北京大学医药管理国际研究中心,北京大学药学院,北京100191 [3]首都医科大学附属复兴医院,北京100038 [4]福建医科大学附属三明第一医院,三明365000

出　　处：《中国新药杂志》2021年第12期1147-1152,共6页Chinese Journal of New Drugs

摘　　要：目的:比较腹腔感染患者使用拉氧头孢、第3代头孢菌素类、β-内酰胺酶抑制剂合剂、碳青霉烯类抗生素的医疗资源使用差异,以期为临床医生优化治疗方案提供参考。方法:利用医院信息系统数据,使用1∶1无放回倾向得分匹配方法筛选基线可比患者,采用匹配后的样本分析组间医疗资源使用差异。结果:本文共纳入4433例样本,倾向得分匹配法(PSM)之后,拉氧头孢组与第3代头孢菌素组成功匹配样本292对,匹配后,拉氧头孢组的次均处方费用比第3代头孢菌素组高1498.6元(P<0.05);拉氧头孢组与β-内酰胺酶抑制剂合剂组成功匹配样本303对,匹配后,与β-内酰胺酶抑制剂合剂组相比,拉氧头孢组的次均住院总费用低12250.9元,次均住院天数少2.6 d(均P<0.05);拉氧头孢组与碳青霉烯组成功匹配样本256对,匹配后,与碳青霉烯组相比,拉氧头孢组的次均处方费用低1470.4元,次均住院总费用低33210.9元,次均住院天数少6.1 d,次均ICU天数少1.4 d(均P<0.05)。结论:腹腔感染患者使用拉氧头孢治疗时比使用β-内酰胺酶抑制剂合剂和碳青霉烯类药物时占用的医疗资源更少,与第3代头孢菌素类药物相比,两者的医疗资源使用情况基本相当。Objective:To compare the difference of medical resource utilization in intra-abdominal infectious patients administered with latamoxef,third-generation cephalosporins,β-lactamase inhibitor compound preparations and carbapenems,and help clinicians improve their treatment strategies.Methods:Based on data from Hospital Information System,a 1∶1 non-replacement propensity score matching(PSM)method was performed to match participants with similar propensity scores between different groups,and the matched participants were adopted to compare their difference in medical resource utilization.Results:A total of 4433 patients were included in this study.292 pairs of patients administered with latamoxef or third-generation cephalosporins were matched by PSM.The average cost of antibiotics in the latamoxef group was 1498.6 yuan higher than that in the third-generation cephalosporins group(P<0.05).303 pairs of patients administered with latamoxef orβ-lactamase inhibitor compound preparations were matched by PSM.Compared with theβ-lactamase inhibitor compound preparations group,the average cost of hospitalization was 12250.9 yuan lower and the average duration of hospitalization was 2.6 days shorter in the latamoxef group(P<0.05).256 pairs of patients administered with latamoxef or carbapenems were matched by PSM.Compared with the carbapenems group,the average cost of antibiotics was 1470.4 yuan lower,the average cost of hospitalization was 33210.9 yuan lower,the average duration of hospitalization was 6.1 days shorter and the mean ICU days was 1.4 days shorter in the latamoxef group(P<0.05).Conclusion:In terms of treating intra-abdominal infection,patients administered with latamoxef showed less medical resource utilization when compared with those withβ-lactamase inhibitor compound preparations and carbapenems,and they showed relatively similar medical resource utilization when compared to those with third-generation cephalosporins.

关 键 词：拉氧头孢 腹腔感染 医疗资源使用 倾向得分匹配法 

分 类 号：R956[医药卫生—药学]